Evotec

EVO

Hamburg, Germany· Est. 1993

evotec.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

EVO · Stock Price

USD 3.24-0.67 (-17.14%)

Market Cap: $1.1B

Historical price data

Market Cap: $1.1BPipeline: 6 drugsPatents: 20Founded: 1993Employees: ~4,800HQ: Hamburg, Germany

Sector Ranking#53 in Digital Health & Biotech SaaS #17 in AI / Machine Learning

Overview

Evotec has evolved from a traditional CRO into a technology-enabled, fully integrated drug discovery and development partner. Its strategy leverages proprietary platforms like PanOmics and iPSC disease modeling, alongside flexible partnership models, to serve the entire Top 20 pharma and over 800 biotechs. Through its Just – Evotec Biologics division, it is also redefining biologics manufacturing with continuous processing to improve accessibility and affordability of therapies.

OncologyNeurologyImmunologyCardiovascular & Metabolic Diseases

Technology Platform

Integrated suite including AI/ML-enhanced Molecular Patient Databases (PanOmics), iPSC-based disease modeling, and the Just – Evotec Biologics continuous bioprocessing platform for end-to-end drug discovery and development.

Pipeline

6 drugs in pipeline

Drug	Indication	Stage
EVT 302, 10 mg + placebo + Nicotine replacement therapy (NRT...	Smoking Cessation	Phase 2
EVT 201	Sleep Initiation and Maintenance Disorders	Phase 2
EVT 302 + Placebo + EVT 302 plus open label Nicotine replace...	Smoking Cessation	Phase 2
EVT 201	Sleep Initiation and Maintenance Disorders	Phase 2
EVT 101 + EVT 101 + placebo	Human Volunteers	Phase 1

Funding History

Total raised:$150M

PIPE$150MUndisclosedJun 15, 2021

IPOUndisclosedUndisclosedJun 15, 1999

Opportunities

Capitalizing on the growing outsourcing trend and shift to data-driven precision medicine through its PanOmics platform.

The disruptive continuous bioprocessing technology from Just – Evotec Biologics addresses a critical need for efficient, affordable biologics manufacturing in a high-growth market.

Risk Factors

Significant dependence on the success of partner and co-owned drug pipelines for milestone revenue.

High capital investment in technology platforms creates pressure to achieve profitability, while intense competition in both AI-discovery and biologics manufacturing poses a constant threat.

Competitive Landscape

Occupies a unique hybrid position, competing with large CROs/CDMOs (e.g., Charles River, Lonza) on scale and tech-enabled discovery platforms (e.g., Recursion, Exscientia) on innovation. Its fully integrated, co-ownership model differentiates it from more transactional service providers.